Preemptive, comprehensive pharmacogenomics testing of cancer patients identifies gene variants that are associated with altered efficacy and toxicity of certain chemotherapy agents and can be integrated into clinical practice in real time, according to clinicians from Mayo Clinic, who described their approach at the 2019 Gastrointestinal Cancers Symposium.
Pharmacogenomics (PGx) is about “selecting the right drug in the right amount for the right patients,” said lead author Pashtoon